About SSI Diagnostica

SSI Diagnostica is a world leader in developing and manufacturing in vitro diagnostic rapid tests with a particular focus on infectious and tropical diseases. The company is also an important partner to vaccine manufacturers worldwide supplying antisera that is crucial for their R&D and quality control efforts. In the Nordics the company additionally leverages its strong footprint to serve as a one stop shop for microbiology laboratories. The company has plaid an important role in the fight against Covid with its high-quality antigen and antibody rapid tests.

The Journey

Commercialization of a formerly state-owned entity leading to strong global growth Key Highlights:
  • Carve-out of state-owned entity and building a new management team
  • Developing a new R&D and commercial strategy focusing the business on antibodies (polyclonal and monoclonal), rapid tests and vaccine manufacturers
  • Transformative acquisition of US based CTK doubling the size of the business and expanding it into tropical diseases and emerging markets as well as providing a high-volume rapid test manufacturing footprint
  • World-leading position in many global niches (pneumococcus, dengue, etc)
  • Meaningful role in fighting Covid through quick development and at scale manufacturing of antigen and antibody rapid tests
  • Sales and EBITDA growth of more than 5x since entry (2016)

Financial Development

38% annualized growth